Slingshot members are tracking this event:

Novartis (NVS) receives first ever FDA approval for a CAR-T cell therapy, Kymriah (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 30, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Car-t Cell Therapy, Kymriah, Ctl019, B-cell All